CONTENTS VOL. 15, 1997

Special issue

Development of Angiogenesis Inhibitors for Cancer Therapy

S.G. Eckhardt and J.M. Pluda, guest editors

Development of angiogenesis inhibitors for cancer therapy – S.G. Eckhardt, J.M. Pluda 1–3

The preclinical evaluation of angiogenesis inhibitors – M.S. O'Reilly 5–13

Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy – S.B. Fox, A.L. Harris 15–29

Angiogenic factors as tumor markers – M. Nguyen 31–39

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents – Y. Kakeji, B.A. Teicher 41–50

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action – *W.J. Gradishar* *51–61*

Matrix metalloproteinase inhibitors – S.M. Wojtowicz-Praga, R.B. Dickson, M.J. Hawkins 63–77

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action – E.A. Woltering, J.C. Watson, R.C. Alperin-Lea, C. Sharma, E. Keenan, D. Kurozawa, R. Barrie 79–86

Instructions for authors 87–88

Preclinical Studies

Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts – T.A. Dunn, H.J. Schmoll, V. Grünwald, C. Bokemeyer, J. Casper 91–98

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice – L. Polin, F. Valeriote, K. White, C. Panchapor, S. Pugh, J. Knight, P. LoRusso, M. Hussain, E. Liversidge, N. Peltier, T. Golakoti, G. Patterson, R. Moore, T.H. Corbett 99–108

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines – T.A. Dunn, H.J. Schmoll, V. Grünwald, C. Bokemeyer, J. Casper 109–114

Phase I Studies

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m^2) and high-dose (875 mg/m^2) levels – C.F. Pollera, A. Ceribelli, M. Crecco, F. Caladresi, C. Oliva 115–121

Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule – R. Pazdur, Y. Lassere, E. Diaz-Canton, B. Bready, D.H. Ho 123–128

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer – E.K. Rowinsky, W.A. Flood, S.E. Sartorius, K.M. Bowling, D.S. Ettinger 129–138

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer – A. Hageboutros, *G.R. Hudes, F. Greene, F.P. LaCreta, James Brennan, P.J. O'Dwyer* *139–145*

Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours – A. Krarup-Hansen, H. Pedersen, E. Andersen, H. Andersen, H.H. Hansen 147–151

Phase II Studies

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell *lung cancer, a southwest oncology group study* – *C.S. Higano, J.J. Crowley, R.V. Veith, R.B. Livingston* 153–156

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder – M. Khorsand, J. Lange, L. Feun, N.J. Clendeninn, M. Collier, G. Wilding 157–163

An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390) – A.N. Leaf, D. Neuberg, E.L. Schwartz, S. Wadler, P.S. Ritch, J.P. Dutcher, G.L. Adams 165–172

Instructions for Authors 173–174

Review Article

Matrix metalloproteinase inhibitors: Present achievements and future prospects – L.J. Denis, J. Verweij 175–185

Preclinical Studies

Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline) – B.J. Foster, L. Jones, R. Wiegand, P.M. LoRusso, T.H. Corbett 187–194

Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS – K.K. Chan, R. Bakhtiar, C. Jiang 195–206

Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice – T.H. Corbett, F.A. Valeriote, L. Demchik, N. Lowichik, L. Polin, C. Panchapor, S. Pugh, K. White, J. Kushner, J. Rake, M. Wentland, T. Golakoti, C. Hetzel, J. Ogino, G. Patterson, R. Moore 207–218

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin – T. Suzuki, S. Minamide, T. Iwasaki, H. Yamamoto, H. Kanda 219–225

Phase I Studies

Unusual central nervous system toxicity in a phase I study of N^1N^{11} diethylnorspermine in patients with advanced malignancy – P.J. Creaven, R. Perez, L. Pendyala, N.J. Meropol, G. Loewen, E. Levine, E. Berghorn, D. Raghavan 227–234

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors – N.T. Sklarin, C.D. Lathia, L. Benson, W.R. Grove, S. Thomas, J. Roca, A.I. Einzig, P.H. Wiernik 235–246

Phase II Studies

Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma – D.S. Richardson, S.M. Kelsey, S.A. Johnson, M. Tighe, J.D. Cavenagh, A.C. Newland 247–253

A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma – M.L. Keohan, M.R. Grever, S.P. Balcerzak, K. Antman 255–256

Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study – J.G. Wall, J.K. Benedetti, M.A. O'Rourke, R.B. Natale, J.S. Macdonald 257–260

Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study – J.K. Benedetti, H.A. Burris III, S.P. Balcerzak, J.S. Macdonald 261–264

Instructions for authors 265–266

Preclinical Studies

Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study – D.J. Stewart, R. Goel, M.C. Cripps, S. Huan, J. Yau, S. Verma 267–277

IL-4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB_{389}-IL-4) – J. Cai, T. Zheng, J. Murphy, C.A. Waters, G.Y. Lin, P.S. Gill 279–287

An *in vitro* assessment of the antineoplastic potential of 2H-1,3-Oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine – L. Seal, D. Von Hoff, R. Lawrence, E. Izbicka, R.M. Jamison 289–293

Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs – M.J. Graziano, G.D. Pilcher, K.M. Walsh, O.B. Kasali, L. Radulovic 295–310

Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by *N*-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism – P.J. Bergman, K.R. Gravitt, N.E. Ward, P. Beltran, K.P. Gupta, C.A. O'Brian 311–318

Phase I Studies

An Eastern Cooperative Oncology Group Phase I trial of all-trans retinoic acid and interferon-alpha: E2Y92 – J.H. Schiller, D. Neuberg, D. Burns, P. Ritch, M. Larson, M. Levitt, J. Dutcher 319–324

Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies – J.D. Hainsworth, S.M. Utley, F.A. Greco 325–329

A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors – R. Brand, M. Capadano, M. Tempero 331–341

Phase II Studies

Long-term response to crisnatol mesylate in patients with glioma – P. New, E. Vokes, L. Rogers, C. Bazan, J. Hohneker, M. Eble, P. Vilk 343–352

A Phase II study of 13-*cis*-retinoic acid in patients with advanced renal cell carcinoma – W.J. Berg, L.H. Schwartz, A. Amsterdam, M. Mazumdar, V. Vlamis, T.M. Law, D.M. Nanus, R.J. Motzer 353–355

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241) – J.S. Macdonald, J.K. Benedetti, M. Modiano, D.S. Alberts 357–359

Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer – J.J. Sharma, B. Razvillas, C.D. Stephens, S.G. Hilsenbeck, A. Sharma, M.L. Rothenberg 361–364

Contents Volume 15, 1997 365–367

Author Index 369–370

Instructions for authors 371–372